CGRP mAb Subcutaneous denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Issued an Experimental/Investigational Denial for Your CGRP Monoclonal Antibody

An experimental or investigational denial from Cigna means the plan's medical policy determined — incorrectly, in most cases for FDA-approved CGRP monoclonal antibodies — that the drug or the specific indication lacks sufficient evidence of clinical effectiveness. This denial type is most likely to appear when the prescribed use is for a condition or patient population outside the labeled indication, such as cluster headache or a comorbid pain syndrome, or when Cigna's policy has not yet been updated to reflect a newly approved indication.

## Why This Denial Is Appealable

If your CGRP antibody carries FDA approval for your specific indication, the experimental label is legally and factually incorrect and should be contested immediately. The FDA's approval determination is based on a rigorous review of safety and efficacy data, and major neurology guideline organizations have endorsed CGRP antibodies for their approved indications. Cigna is required to evaluate its own policy against current medical evidence and FDA status; a prescriber letter citing the approval and referencing the applicable guideline organization will frequently reverse this denial at the internal level.

## Your Federal Appeal Rights

• ACA §2719 external review is particularly powerful here: an independent reviewer will assess whether the denial meets the evidentiary standard for an experimental exclusion. Cigna's determination must be consistent with generally accepted medical standards.
• ERISA §503 applies to self-funded plans and requires timely, reasoned review.
• The external-review window is generally approximately four months after final internal denial — do not delay filing the internal appeal.
• Request expedited review if your condition is causing significant functional impairment or frequent emergency visits.

## Documentation to Gather

• FDA approval status: print the current FDA label from DailyMed (dailymed.nlm.nih.gov) confirming approval for your specific indication; include this as Exhibit A.
• Applicable guideline endorsement: a one-sentence reference to the relevant professional society (e.g., the American Headache Society or applicable neurology body) that includes this drug class in its current treatment recommendations — obtain exact language from the current published guideline.
• Prescriber medical-necessity letter: must state the FDA-approved indication, cite the guideline, and explain that this drug class is the standard of care for this patient's condition.
• Cigna's policy document: obtain and cite the exact experimental-exclusion criteria from Cigna's current CGRP medical coverage policy; demonstrate point-by-point that none of those criteria apply.

## Criteria-Mapping Structure

Build your appeal around a table that directly rebuts the experimental finding:

| Cigna Experimental Criterion | Rebuttal with Source | |---|---| | Not FDA-approved for this indication | FDA label, DailyMed link, date of approval | | Insufficient evidence of clinical benefit | Guideline organization endorsement, current policy language | | Not accepted by qualified experts | Prescriber specialty + letter citing standard-of-care consensus |

Always cross-reference the current FDA prescribing information and Cigna's most recently published coverage policy before submitting; policy language can change, and your appeal must respond to the version currently in force.